$Inhibikase Therapeutics (IKT.US)$ $Inhibikase Therapeutics ...
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar(CWBR.US$
$CohBar(CWBR.US$
..........................................
$Fulcrum Therapeutics(FULC.US$
$Fulcrum Therapeutics(FULC.US$
$Fulcrum Therapeutics(FULC.US$
🚀🚀🚀🚀🚀🚀🚀🚀
$Nautilus Biotechnology(NAUT.US$
$Bit Digital(BTBT.US$
$NeuroMetrix(NURO.US$
$Chembio Diagnostics(CEMI.US$
$Starboard Value Acquisition(SVAC.US$
$Paysafe(PSFE.US$
$NeuroMetrix(NURO.US$
$GlaxoSmithKline(GSK.US$
$Chembio Diagnostics(CEMI.US$
$IGC Pharma(IGC.US$
$Paysafe(PSFE.US$
$QELL ACQUISITION CORP(QELL.US$
$Bridgetown Holdings Ltd(BTWN.US$
$SNDL Inc(SNDL.US$
$NeuroMetrix(NURO.US$
$Nokia Oyj(NOK.US$
$Starboard Value Acquisition(SVAC.US$
$Bridgetown Holdings Ltd(BTWN.US$
$Pharming Group(PHAR.US$
$EZGO Technologies(EZGO.US$
$Xenetic Biosciences(XBIO.US$
$SCORE MEDIA AND GAMING INC.(SCR.US$
$Zymergen, Inc.(ZY.US$
$BlackBerry(BB.US$
$SiTime(SITM.US$
$Astra Space(ASTR.US$
$Ampio Pharmaceuticals(AMPE.US$
$Bit Digital(BTBT.US$
$Bit Digital(BTBT.US$
$Bit Digital(BTBT.US$
$NeuroMetrix(NURO.US$
$Chembio Diagnostics(CEMI.US$
$Starboard Value Acquisition(SVAC.US$
$Paysafe(PSFE.US$
$NeuroMetrix(NURO.US$
$GlaxoSmithKline(GSK.US$
$Chembio Diagnostics(CEMI.US$
$IGC Pharma(IGC.US$
$Paysafe(PSFE.US$
$QELL ACQUISITION CORP(QELL.US$
$Bridgetown Holdings Ltd(BTWN.US$
$SNDL Inc(SNDL.US$
$NeuroMetrix(NURO.US$
$Nokia Oyj(NOK.US$
$Starboard Value Acquisition(SVAC.US$
$Bridgetown Holdings Ltd(BTWN.US$
$Pharming Group(PHAR.US$
$EZGO Technologies(EZGO.US$
$Xenetic Biosciences(XBIO.US$
$SCORE MEDIA AND GAMING INC.(SCR.US$
$Zymergen, Inc.(ZY.US$
$BlackBerry(BB.US$
$SiTime(SITM.US$
$Astra Space(ASTR.US$
$Ampio Pharmaceuticals(AMPE.US$
$Bit Digital(BTBT.US$
$Bit Digital(BTBT.US$
kepos capital bought 700,000 shares, bull soon🐂🐂
Ex–Goldman Sachs
Quant Mark Carhart Is
Launching A New Firm
Quant Mark Carhart Is
Launching A New Firm
By launching Kepos Capital, Carhart aims to prove that quantitative global macro is stronger than ever.
$Goldman Sachs(GS.US$
$Goldman Sachs(GS.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
supastarcwet23 : we keep thinking black rock is good under your stock..those are the same people shorting under every stock and I've notice their name comes up with a lot of manipulation stocks..crazy man